Articles On Imugene (ASX:IMU)

Title Source Codes Date
Do you own the 3 best performing ASX 200 shares of FY 2025?

The S&P/ASX 200 Index (ASX: XJO) is up 2.5% and in new all-time high territory as we near the end of the second trading week of FY 2025. But some ASX shares have already done much better. Now, two weeks is only a small snapshot for thes...

Motley Fool IMU 6 days ago
Buy Coles and these ASX 200 dividend stocks in July

If you're building an income portfolio, then it could be worth looking at the ASX 200 dividend stocks named below. Here's why they could be good options for income investors this month: Cedar Woods Properties Limited (ASX: CWP) Morgans th...

Motley Fool IMU 6 days ago
Why I keep buying shares of this 5%-yielding ASX dividend stock

There's an ASX dividend stock on the market right now that, until very recently, was yielding close to 5%. This particular ASX 200 blue chip has rallied significantly over the past few weeks, which has now pushed down its dividend yield clo...

Motley Fool IMU 1 week ago
Telstra stock pays a massive 7% dividend, and now could be a great time to buy

Telstra Group Ltd (ASX: TLS) stock is regularly viewed as an appealing ASX dividend share to own. This could be a compelling time to consider the company for its passive income and dividend potential. Businesses that are able to deliver...

Motley Fool IMU 1 week ago
Here are the top 10 ASX 200 shares today

It was a sobering Wednesday session for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares today. After recording a strong gain yesterday, investors appear to hav...

Motley Fool IMU 1 week ago
Imugene delivers first Aussie bile tract cancer trial dose

Imugene has dosed its first of 10 Australian patients with its potent “VAXINIA” therapy as part of its phase-one bile tract cancer trial being conducted at St Vincent’s Hospital in Melbourne.

The West IMU 1 week ago
This Warren Buffett metric is at a never-before-seen high! What does it mean?

The S&P 500 Index (SP: .INX) and Nasdaq Composite Index (NASDAQ: .IXIC) reached new all-time highs on Wall Street last night. It should be a cause for celebration. If only the record weren't accompanied by a more sinister number crack...

Motley Fool IMU 1 week ago
Have you heard of this ASX robotics stock? It's up 75% in 3 days!

The market is having a bit of a subdued session on Wednesday, but that isn't stopping one ASX robotics stock from storming higher again. At the time of writing, the FBR Ltd (ASX: FBR) share price is up 19% to 5.6 cents. This means that its...

Motley Fool IMU 1 week ago
ASX Market Update: Telcos strong in weak market | 10 July 2024

The ASX is down 0.3% to 7,807 points heading into lunchtime trade. Telecommunications is the only sector in the green up 0.9%. This is on the back of Telstra’s pricing announcement released yesterday. All other sectors are in the red wit...

themarketonline.com.au IMU 1 week ago
Imugene (ASX: IMU) doses first patient in Phase 1 bile tract cancer trial

Highlights The first patient in the Phase 1 bile tract cancer trial has been dosed. The trial is expected to enrol 10 patients with bile tract cancer. The sixth high dose cohort of both arms of the Phase 1 MAST monotherapy dose escala...

Kalkine Media IMU 1 week ago
2 ASX shares roaring higher on big news

The market may have run out of steam on Wednesday, but not all ASX shares are falling. Two that are catching the eye of investors and roaring higher this morning are listed below. Here's why investors have been buying their shares today: D...

Motley Fool IMU 1 week ago
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Stockhead IMU 2 weeks ago
Imugene delivers first combo dose in bile tract cancer study

Imugene has confirmed the delivery of its first “onCARlytics” combination therapy dose to a bile duct cancer patient in the initial phase of a world-first trial at the City of Hope medical centre in the US.

The West IMU 3 weeks ago
Imugene (ASX: IMU) begins Phase 1 onCARlytics trial with first IV infusion

Highlights The first patient has received treatment under the intravenous (IV) infusion combination arm of the Phase 1 onCARlytics trial. The trial aims to enrol nearly 40-45 patients with advanced solid cancers that have spread. Prel...

Kalkine Media IMU 3 weeks ago
Imugene doses first cancer patient in Oasis trial

Imugene Limited (ASX: IMU), has dosed the first patient in the phase 1 clinical trial known as OASIS, which is testing its oncolytic virotherapy drug. The clinical trial is targeting adult patients with advanced or metastatic solid tumou...

themarketonline.com.au IMU 3 weeks ago
ASX Market Open: ASX to fall on a mixed US performance and questions about AI-rally viability

The ASX200 is set to fall today, influenced by a mixed US market performance on Friday, which itself was shaped by questions about the long-term viability of the AI-driven rally, and whether the US economy was moderating. At 8.45 am AEST...

themarketonline.com.au IMU 3 weeks ago
May In Review: Inflation Spoils The ASX Party

Overseas markets rallied in May on lower bond yields and stabilising inflation prints, but the Australian market couldn't sustain the early May up-swing, weighed down by a surprisingly high April CPI reading and some negative earnings updat...

FNArena IMU 1 month ago
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Stockhead IMU 1 month ago
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Stockhead IMU 1 month ago
From high-tech cancer fighters to AI-wielding crime busters, these are some of the most innovative firms on the ASX

Special Report: A recent lunch put together in Sydney by Jane Morgan Management and Éthica Capital saw a number of the ASX’s most innovative biotech and tech companies present and pitch to an audience of potential investors on the lookout f...

Stockhead IMU 2 months ago
Up close and personal with ASX tech and Biotech

Investors got the chance to get up close and personal with ASX technology and biotech companies in Sydney recently at the JMM & Ethica Capital Innovation & Investment Insights Lunch. Featuring quick ‘stand up and pitch your story’ s...

Stockhead IMU 2 months ago
Imugene (ASX: IMU) March quarter roundup: clinical trial progress, patent grant and strategic partnership

Highlights Under the Phase 1 MAST trial high cohort dose, dosing of first patients has been concluded. Bile tract cancer expansion study opened. Dosing commenced in the OnCARlytics (CF33-CD19) trial. Imugene joined hands with Kincell...

Kalkine Media IMU 2 months ago
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

Stockhead IMU 2 months ago
3 ASX healthcare shares outperforming on quarterly updates

S&P/ASX 200 Health Care (ASX: XHJ) shares are up 0.44% on Tuesday while the ASX 200 is up 0.23%. But these three ASX healthcare shares are knocking it out of the park on this otherwise lacklustre day. Here's why. Paradigm Bio...

Motley Fool IMU 2 months ago
Why are Pointsbet shares crashing 45% today?

Pointsbet Holdings Ltd (ASX: PBH) shares are having a very tough session on Tuesday. In morning trade, the sports betting company's shares crashed as much as 45% to 45.5 cents. The company's shares have recovered a touch since then but rema...

Motley Fool IMU 2 months ago
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Stockhead IMU 2 months ago
2 ASX betting shares surging on quarterly updates

There have been a couple of big moves in the betting industry on Wednesday following the release of quarterly updates. Let's dig a little deeper into these releases now and see what's getting investors excited: Bluebet Holdings Ltd (ASX: B...

Motley Fool IMU 2 months ago
Broker says this ASX biotech stock could almost double in value

If you're the type of investor that likes high risk-high reward investments, then read on. That's because a leading broker is tipping an ASX biotech stock to almost double in value over the next 12 months. The company in question is Imugene...

Motley Fool IMU 2 months ago
Imugene's (ASX: IMU) strategic partnership with Kincell Bio: Charting path to clinical progress

Highlights Imugene's partnership with Kincell Bio is aimed at accelerating the development of innovative immunotherapies. Sale of Imugene's North Carolina facility to Kincell Bio would streamline operations and reduce costs. Collabora...

Kalkine Media IMU 2 months ago
Closing Bell: A big relief rally for the ASX today; copper continues its bull market rally

The ASX staged a relief rally on Monday Gold, oil stocks struggled after tensions in the Middle East eased The focus has now shifted from Middle East tensions to company earnings   The ASX put on a relief rally after its -3% loss last wee...

Stockhead IMU 2 months ago
Market Close: ASX launches liferafts in a sea of red and wounded

After shedding nearly double what futures had predicted, the ASX200 closed the day 1.8 per cent down. At one stage the ASX was on track for its worst day in 13 months and at the close, real estate, consumer stocks and mining were all lickin...

themarketonline.com.au IMU 3 months ago
Imugene cancer fight bolstered by strategic US partnership

Australian anti-cancer company Imugene has stamped a strategic manufacturing deal with Kincell Bio, with the latter agreeing to purchase the company’s North Carolina facility for US$6 million (AU$9.34 million).

The West IMU 3 months ago
Imugene (ASX: IMU) teams up with Kincell Bio to drive efficiencies and savings

Highlights The strategic manufacturing and process development collaboration involves the sale of IMU's CGMP manufacturing facility in North Carolina to Kincell. Kincell will acquire the facility for up to US$6 million in upfront and m...

Kalkine Media IMU 3 months ago
Imugene launches pivotal bile tract cancer expansion study

ASX-listed med-tech company Imugene has launched a pivotal expansion study targeting patients with bile tract cancer following encouraging results from its Metastatic Advanced Solid Tumours trial.

The West IMU 3 months ago
Market Update: Star’s tumble as NSW Inquiry ramps up

There’s no surprises on market today, the ASX200 has been down around half a per cent – on par with the morning’s predictions. The Energy and Materials sectors have been showing resilience, energy’s up about 0.4% and mining stocks by abo...

themarketonline.com.au IMU 3 months ago
ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer’s

Atomo announces more purchase orders for HIV Self-Tests Actinogen says first patient was treated in Alzheimer’s disease study Imugene has opened enrolment for expansion study in solid tumours   Atomo sells more HIV self-test kits Atomo Di...

Stockhead IMU 3 months ago
Imugene (ASX: IMU) begins enrolment for bile tract cancer expansion trial

Highlights Bile tract cancer expansion study opens after the completion of the high dose cohort in the MAST trial. This new trial aims to enrol 10 patients with bile tract cancers, specifically cholangiocarcinoma. Interim findings fro...

Kalkine Media IMU 3 months ago
Imugene expands study for bile tract cancer patients

Cancer immunotherapy company Imugene Ltd (ASX: IMU) will be expanding its trial for the use of CF33-hNIS (VAXINIA) to treat gastrointestinal cancers – including bile tract cancer (also known as (cholangiocarcinoma) – and is now enrolling te...

themarketonline.com.au IMU 3 months ago
How has the Liontown share price rocketed 15% in a week?

It's been a decent week for the S&P/ASX 200 Index (ASX: XJO). Since last Thursday, the ASX 200 has gained a healthy 1.05%. But that's nothing compared to the gains of the Liontown Resources Ltd (ASX: LTR) share price. Liontown shares ha...

Motley Fool IMU 3 months ago
These ASX 300 mining stocks could rise 25% to 50%

If you're not averse to investing in the mining sector and want big returns for your portfolio, then read on. That's because analysts at Bell Potter have just put buy ratings on two ASX 300 mining stocks and are tipping potential upside of...

Motley Fool IMU 3 months ago
Imugene (ASX: IMU) presents VAXINIA and HER-Vaxx at AACR annual meeting

Highlights IMU’s CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx to showcased at the American Association for Cancer Research (AACR) Annual Meeting. The oncolytic virus CF33-hNIS (VAXINIA), either alone or combined...

Kalkine Media IMU 3 months ago
The ASX 200 lithium stock this fundie is backing for the global lithium comeback

If you owned S&P/ASX 200 Index (ASX: XJO) lithium stocks in 2021 and 2022, you likely enjoyed some outsized share price gains at the time. That period saw a massive increase in lithium demand amid strong growth in global battery market...

Motley Fool IMU 3 months ago
Bell Potter names the best ASX 200 shares to buy in April

If you're in the market for some new ASX 200 shares in April, then it could be worth listening to what analysts at Bell Potter are saying. That's because they have just revealed their favoured picks for the month ahead. Two on its list th...

Motley Fool IMU 3 months ago
Imugene locks down cancer patent in massive Chinese market

Australian anti-cancer company Imugene has received a patent to protect its unique cancer treatment in China – the largest and most lucrative pharmaceutical market in Asia.

The West IMU 3 months ago
Here are the top 10 ASX 200 shares today

It was a happy Thursday for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares today, with investors shaking off the midweek blues that we saw yesterday. By the end of trading this sessi...

Motley Fool IMU 3 months ago
Why Imugene, Liontown, Pointsbet, and Regis Resources shares are storming higher

The S&P/ASX 200 Index (ASX: XJO) is bouncing back from yesterday's horror session and is pushing higher in afternoon trade. At the time of writing, the benchmark index is up 0.5% to 7,822.5 points. Four ASX shares that are rising more...

Motley Fool IMU 3 months ago
Imugene (ASX: IMU) shares up on Chinese patent for oncolytic virotherapy CF33

Highlights A Notice of Grant received from the Chinese Patent Office for IMU’s oncolytic virotherapy CF33. Previously, grants were obtained in South Korea and Japan. The patents extend protection for the method of composition and meth...

Kalkine Media IMU 3 months ago
Imugene's oncolytic virotherapy CF33 patent granted in China

Clinical stage immunooncology company Imugene (ASX:IMU) has received a Notice of Grant from the Chinese Patent Office, following earlier Grants in Japan and South Korea.

BiotechDispatch IMU 3 months ago
Imugene picks up new virotherapy patent in China

Imugene (ASX:IMU) has announced its receipt of a new patent in China. The Chinese regulator – Asia’s largest pharmaceutical market – has approved a patent for Imugene’s oncolytic virotherapy drug CF33. Oncolytic virotherapy relates to...

themarketonline.com.au IMU 3 months ago
Guess which ASX 300 healthcare stock is storming higher on Chinese patent news

Imugene Ltd (ASX: IMU) shares are catching the eye on Thursday morning. In early trade, the ASX 300 healthcare stock is up almost 5% to 11 cents. Why is this ASX 300 healthcare stock storming higher? Investors have been buying the clinical...

Motley Fool IMU 3 months ago